Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-07-16 pm EDT 5-day change 1st Jan Change
151 USD +1.19% Intraday chart for Johnson & Johnson +2.69% -3.66%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
EQT Unit Invests in Biotechnology Company Asceneuron MT
Equity Markets Higher After Fed Chair Powell's Comments MT
Equity Markets Rise Intraday After Fed Chair Powell's Comments MT
Stocks Gain Pre-Bell Ahead of Key Earnings; Asia Mixed, Europe Down MT
Brace for a flurry of speeches from Fed officials Our Logo
Certain Common Stock of Kenvue Inc. are subject to a Lock-Up Agreement Ending on 14-JUL-2024. CI
J&J: completes acquisition of Yellow Jersey for $1.25 billion CF
Johnson & Johnson Completes Acquisition of Yellow Jersey Therapeutics MT
Mixed feelings Our Logo
Emergent Biosolutions, Johnson & Johnson Settle Dispute Over COVID-19 Vaccine Manufacturing MT
Indivior shares dive on profit warning, dropping of schizophrenia drug (July 9) RE
Emergent, J&J settle COVID vaccine supply deal dispute RE
Emergent Biosolutions to Get $50 Million from Covid-19 Manufacturing Settlement with Johnson & Johnson Unit DJ
J&J to pay $50 million to Emergent to resolve manufacturing deal for COVID vaccine RE
The battle over J&J's bankruptcy plan to end talc lawsuits RE
Stryker Corporation : Major Player in Medical Devices Our Logo
Johnson & Johnson's Rybrevant Approved by Health Canada to Treat Advanced Lung Cancer MT
Johnson & Johnson Lung Cancer Drug Gets Health Canada Approval DJ
J&J: full approval for Sirturo in tuberculosis CF
J&J: promising results in multiple myeloma CF
Johnson & Johnson Says Interim Analysis of Blood Cancer Therapy Study Show Promise MT
Johnson & Johnson Announces Positive Results from Prespecified Second Interim Analysis of the Phase 3 CARTITUDE-4 Study Evaluating CARVYKTI CI
Momentum Picks Q3 2024: 5 stocks for the summer Our Logo
New semester, new state of mind Our Logo
Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial MT
Chart Johnson & Johnson
More charts
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
151 USD
Average target price
171.5 USD
Spread / Average Target
+13.56%
Consensus
  1. Stock Market
  2. Equities
  3. JNJ Stock
  4. News Johnson & Johnson
  5. Johnson & Johnson's Balversa Gets EU Panel Recommendation for Urothelial Carcinoma